Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study.

@article{Stefoni2005EfficacyAS,
  title={Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study.},
  author={Sergio Stefoni and Karsten Midtved and Edward I. Cole and Eric Thervet and Sandra L Cockfield and Matthias Buchler and Lorenzo Toselli and Luis Manuel Pallard{\'o} and Francesco Paolo Schena and Helen Pilmore and Mich{\`e}le Kessler and Steve C Chadban and C{\'e}sar Agost Carre{\~n}o},
  journal={Transplantation},
  year={2005},
  volume={79 5},
  pages={577-83}
}
BACKGROUND The clinical benefits of C2 monitoring of cyclosporine microemulsion have been demonstrated, but C2 targets in renal transplant recipients during the first year require validation. METHODS MO2ART was a prospective, multicenter study of renal transplant recipients managed by C2 monitoring of cyclosporine microemulsion with steroids and mycophenolate mofetil or azathioprine. Patients were randomized on day 3 to two groups, which were managed from month 3 with higher or lower C2… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.

Transplant international : official journal of the European Society for Organ Transplantation • 2007
View 11 Excerpts
Highly Influenced

Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…